A study comparing CD19-targeting CAR T cell and CAR PB-NK cell anti-leukemia responses in vivo demonstrated prolonged survival and reduced adverse effects in mice treated with the CAR-NK cell product, highlighting the potential of CAR-NK therapy in CD19+ malignancies (216). Here, CD19 is linked to leukemia.